Presentation is loading. Please wait.

Presentation is loading. Please wait.

SiRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide  Jonathan E. Zuckerman,

Published byElvin Owen Modified over 5 years ago

Similar presentations

Presentation on theme: "SiRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide  Jonathan E. Zuckerman,"— Presentation transcript:

1 siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide  Jonathan E. Zuckerman, Teli Hsueh, Richard C. Koya, Mark E. Davis, Antoni Ribas  Journal of Investigative Dermatology  Volume 131, Issue 2, Pages (January 2011) DOI: /jid Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

2 Figure 1 Knockdown of ribonucleotide reductase subunit-2 (RRM2) mRNA and protein expression by small interfering RNA (siRNA) siR2B+5 in melanoma cells. (a) Quantitative real-time reverse transcription PCR analysis of RRM2 mRNA levels in HT-144 cells 48hours after transfection with 5nmoll−1 of RRM2-targeted siRNA (siR2B+5) or a non-targeting control (siCON) siRNA (error bars, n=3). (b) Quantification of RRM2 protein expression by western blot band densitometry analysis, average of three independent experiments; one blot is pictured (error bars, n=3). 5′-RNA ligand-mediated rapid amplification of complementary DNA ends detection of siRNA induced mRNA cleavage fragment HT-144 cells transfected using either (c) LipofectamineRNAiMax or (d) targeted cyclodextrin-containing polymer (CDP)/siRNA nanoparticles (arrows point to position of the predicted 209bp amplicon). (e) Sequencing chromatographs from positive rapid amplification of complementary DNA end bands. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

3 Figure 2 In vitro antiproliferative effects of ribonucleotide reductase subunit-2 knockdown by siR2B+5 small interfering RNA (siRNA) in a panel of melanoma cell lines. (a) Bioluminescent-based viability assay on a panel of cell lines 72hours after transfection with 5nmoll−1 siRNAs, siR2B+5 (black columns), or siCON (white columns). Cell line oncogenic mutations are indicated by (*) NRAS codon 61 mutation, (+) BRAF V600E mutation, or (¶) NRAS/BRAF wild type. (b) MTS viability assay of M202 melanoma cells transfected with a range of siR2B+5 concentrations from to 50nmoll−1 (black circles), or siCON 0.5–50nmoll−1 (white circles) performed at 48, 72, 96, and 120hours following transfection (only the 120-hour siCON time points are displayed). All cell viability data are normalized to untreated control samples (error bars, n=3). Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

4 Figure 3 G1/S-phase cell cycle arrest, but little apoptosis, is induced by siR2B+5 small interfering RNA ribonucleotide reductase subunit-2 knockdown. (a) Propidium idodide cell cycle analysis of HT-144 melanoma cells 48hours after treatment with 5nmoll−1 siR2B+5 or siCON; histograms are representative of at least three independent experiments. (b) Annexin-V-FITC/propidium iodide apoptosis analysis of HT-144 cells 72hours after treatment with 2.5 or 5nmoll−1 of siR2B+5, siCON, or staurosporin (SSP, positive control). Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

5 Figure 4 Cell cycle arrest profiles vary between different melanoma cell lines, despite similar level of siR2B+5 small interfering RNA (siRNA) knockdown of ribonucleotide reductase subunit-2 expression. Propidium iodide cell cycle analysis of (a) M202 or (b) M207 melanoma cell lines 48hours after treatment with 5nmoll−1 siR2B+5 or siCON siRNA. Western blot analysis of (c) M202 or (d) M207 cells 48hours after transfection with 5nmoll−1 siR2B+5 siRNA in the presence of lipofectamine RNAiMax. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

6 Figure 5 Synergy between siR2B+5 and temozolomide treatment. Bioluminescence-based cell viability analysis of M202 cells (a) or HT-144 cells (b) 72hours after treatment with increasing doses of siR2B+5 (nmoll−1) (triangular boxes), temozolomide-sol (nmoll−1) (circular boxes), or co-treatment with both agents (square boxes). Data are normalized to an untreated sample. Synergy analysis of M202 (c) and HT-144 (d) cell viability data following co-treatment with siR2B+5 siRNA and temozolomide using the combination index (CI) method. CI values <1 indicate synergy. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

Download ppt "SiRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide  Jonathan E. Zuckerman,"

Similar presentations

SiRNA Knockdown of Tissue Inhibitor of Metalloproteinase-1 in Keloid Fibroblasts Leads to Degradation of Collagen Type I  Masayo Aoki, Koichi Miyake,

SiRNA Knockdown of Tissue Inhibitor of Metalloproteinase-1 in Keloid Fibroblasts Leads to Degradation of Collagen Type I  Masayo Aoki, Koichi Miyake,
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells  Y. Linda Wu, Uday Bhanu.

Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells  Y. Linda Wu, Uday Bhanu.
Amanda M. Nelson, Kathryn L. Gilliland, Zhaoyuan Cong, Diane M

Amanda M. Nelson, Kathryn L. Gilliland, Zhaoyuan Cong, Diane M
A Signal Transduction Pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its Correlation with Progression in Human Melanoma  Xuan Qu, Liangliang Shen,

A Signal Transduction Pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its Correlation with Progression in Human Melanoma  Xuan Qu, Liangliang Shen,
Volume 135, Issue 3, Pages (September 2008)

Volume 135, Issue 3, Pages (September 2008)
Inhibition of the Prohormone Convertase Subtilisin-Kexin Isoenzyme-1 Induces Apoptosis in Human Melanoma Cells  Nina Weiß, Agatha Stegemann, Marwa A.T.

Inhibition of the Prohormone Convertase Subtilisin-Kexin Isoenzyme-1 Induces Apoptosis in Human Melanoma Cells  Nina Weiß, Agatha Stegemann, Marwa A.T.
Yongping Shao, Kaitlyn Le, Hanyin Cheng, Andrew E. Aplin 

Yongping Shao, Kaitlyn Le, Hanyin Cheng, Andrew E. Aplin 
Xeroderma Pigmentosum Group A Promotes Autophagy to Facilitate Cisplatin Resistance in Melanoma Cells through the Activation of PARP1  Rui Ge, Lin Liu,

Xeroderma Pigmentosum Group A Promotes Autophagy to Facilitate Cisplatin Resistance in Melanoma Cells through the Activation of PARP1  Rui Ge, Lin Liu,
Myocardin-Related Transcription Factors A and B Are Key Regulators of TGF-β1- Induced Fibroblast to Myofibroblast Differentiation  Beverly J. Crider, George.

Myocardin-Related Transcription Factors A and B Are Key Regulators of TGF-β1- Induced Fibroblast to Myofibroblast Differentiation  Beverly J. Crider, George.
Modification of Alternative Splicing of Mcl-1 Pre-mRNA Using Antisense Morpholino Oligonucleotides Induces Apoptosis in Basal Cell Carcinoma Cells  Jeng-Jer.

Modification of Alternative Splicing of Mcl-1 Pre-mRNA Using Antisense Morpholino Oligonucleotides Induces Apoptosis in Basal Cell Carcinoma Cells  Jeng-Jer.
RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells  Anja Berger, Sandra-Annika Quast, Michael Plötz, Nicholas-Frederik Kuhn,

RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells  Anja Berger, Sandra-Annika Quast, Michael Plötz, Nicholas-Frederik Kuhn,
C-CBL E3 Ubiquitin Ligase Is Overexpressed in Cutaneous T-Cell Lymphoma: Its Inhibition Promotes Activation-Induced Cell Death  Jianqiang Wu, Katrin A.

C-CBL E3 Ubiquitin Ligase Is Overexpressed in Cutaneous T-Cell Lymphoma: Its Inhibition Promotes Activation-Induced Cell Death  Jianqiang Wu, Katrin A.
Verena N. Lorenz, Michael P. Schön, Cornelia S. Seitz 

Verena N. Lorenz, Michael P. Schön, Cornelia S. Seitz 
Adenosine- and Adenine-Nucleotide-Mediated Inhibition of Normal and Transformed Keratinocyte Proliferation is Dependent upon Dipyridamole-Sensitive Adenosine.

Adenosine- and Adenine-Nucleotide-Mediated Inhibition of Normal and Transformed Keratinocyte Proliferation is Dependent upon Dipyridamole-Sensitive Adenosine.
Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells  Edgar Selzer, Emilio Pimentel, Volker Wacheck, Werner Schlegel,

Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells  Edgar Selzer, Emilio Pimentel, Volker Wacheck, Werner Schlegel,
Reduction of CRKL expression in patients with partial DiGeorge syndrome is associated with impairment of T-cell functions  Mauro Giacomelli, PhD, Rajesh.

Reduction of CRKL expression in patients with partial DiGeorge syndrome is associated with impairment of T-cell functions  Mauro Giacomelli, PhD, Rajesh.
Volume 135, Issue 3, Pages (September 2008)

Volume 135, Issue 3, Pages (September 2008)
The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells  Stuart J. Gallagher, Branka Mijatov,

The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells  Stuart J. Gallagher, Branka Mijatov,
SOX10 Promotes Melanoma Cell Invasion by Regulating Melanoma Inhibitory Activity  Saskia A. Graf, Christian Busch, Anja-Katrin Bosserhoff, Robert Besch,

SOX10 Promotes Melanoma Cell Invasion by Regulating Melanoma Inhibitory Activity  Saskia A. Graf, Christian Busch, Anja-Katrin Bosserhoff, Robert Besch,
Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells  Nabanita Mukherjee, Steven.

Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells  Nabanita Mukherjee, Steven.

Similar presentations

Ads by Google